Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Centre Leon Berard
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05096390CT.gov Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC | — | Recruiting | — | — | — |
NCT04033991CT.gov Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. | — | Completed | — | — | — |
NCT02489695CT.gov Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Papillary Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Axitinib (this asset) | Centre Leon Berard | P2 | B · 57 |
| Irinotecan | National Cancer Institute (NCI) | P2 | BB |
| Cyclophosphamide | First Affiliated Hospital, Sun Yat-Sen University | P3 | BB |
| Pembrolizumab | First Affiliated Hospital, Sun Yat-Sen University | P3 | BB |
| Cabozantinib | National Cancer Institute (NCI) | P2 | BB |
| Volitinib | AstraZeneca | P3 | BB |
| Durvalumab | AstraZeneca | P3 | B |
| Crizotinib | National Cancer Institute (NCI) | P2 | B |
| Sorafenib | National Cancer Institute (NCI) | P2 | B |
+27 more in the Papillary Renal Cell Carcinoma cohort
Other indications for Axitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Kidney Neoplasm | — | P3 | BB · 69 |
| Renal Cell Carcinoma | — | P4 | BB · 67 |
| Kidney Cancer | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Axitinib in Papillary Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/axitinib-papillary-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →